Investor Alert

Sept. 21, 2020, 2:35 a.m. EDT

AstraZeneca drug recommended for ovarian cancer

By Anthony O. Goriainoff

AstraZeneca PLC said on Monday that its Lynparza drug has been recommended for approval in the European Union as first-line maintenance treatment for HRD-positive advanced ovarian cancer, and that it has also been recommended for marketing authorization by the EU for patients with metastatic castration-resistant prostate cancer.

The FTSE 100-listed drug maker also said that results from a prespecified exploratory analysis of the positive ADAURA phase 3 trial showed its Tagrisso drug demonstrated a clinically-meaningful improvement in central nervous system disease-free survival in patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection. The company said Tagrisso also reduced the risk of disease recurrence in the brain by 82% in the adjuvant treatment of early-stage epidermal growth factor receptor-mutated lung cancer.

The company said that advanced ovarian cancer patients treated with Lynparza and drug bevacizumab lived without disease progression for a median of 37.2 months versus 17.7 months for bevacizumab alone.

The pharmaceutical company also said that for patients with advanced ovarian cancer, the primary aim of first-line treatment is to delay disease progression for as long as possible with the intent to achieve long-term remission.

Link to MarketWatch's Slice.